GTx raises $47.5 M to advance Ostarine in cancer-wasting and partner Capesaris
28 June 2011
Nancy Faigen
Please Login to read the full article.
28 June 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- GTx shares dive as clot threat brings FDA clinical hold for prostate cancer product
- GTx investors powered up over US FDA nod for Phase III muscle wasting trials
- Iron chelator, prostate cancer conundrum on deck for ODAC
- GTx lowers dose in attempt to lift hold on prostate cancer drug
ANALYSIS
Other Informa Analysis
FEATURES
Other Informa Features
EVENTS
Today
Le Plaza Hotel, Brussels, Belgium
Today
Diplomat Hotel, Prague, Czech Republic
Today
Business Design Centre, London
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
